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Background: Long-term alendronate therapy may lead to atypical femoral fractures in a very few patients. However,
the management protocol to optimize fracture healing remains undetermined. The purpose of this study was to
describe the time to union of atypical femoral fractures after surgical nailing in patients on long-term alendronate
therapy, with continuation of alendronate or discontinuation of alendronate, and administration of bone-forming agents.
Findings: From January 2004 to December 2011, the records of patients at our institution on long-term alendronate
therapy for more than 36 months and sustaining atypical femoral fractures that had undergone surgical nailing, with
continuation of alendronate or discontinuation of alendronate and administration of bone-forming agents were
reviewed.
During the 8-year study period, we treated 10 atypical femoral fractures with surgical nailing in 7 consecutive osteopenic
or osteoporotic patients on long-term alendronate therapy for more than 36 months. There were no post-operative
complications or needs for revision surgery. All fractures achieved union during follow-up. Mean union time was
23.5 months (range, 18–31 months) for 6 fractures with continuation of alendronate after surgery, and 4.5 months
(range, 4–5 months) for 4 fractures with discontinuation of alendronate and administration of bone-forming agents after
surgery.
Conclusions: Discontinuation of alendronate and administration of bone-forming agents after surgical nailing may
promote union of atypical femoral fractures in patients on long-term alendronate therapy.
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Background
Postmenopausal osteoporosis is commonly treated with
alendronate, one of the bisphosphonates used for the pre-
vention and treatment of osteoporotic fractures. However,
long-term alendronate therapy may lead to atypical femoral
fractures in a very few patients, but the management proto-
col to optimize fracture healing remains undetermined.* Correspondence: ritsai8615@gmail.com
Department of Orthopaedic Surgery, China Medical University Hospital,
School of Medicine, China Medical University, Taichung, Taiwan
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reproduction in any medium, provided the orPrior studies reported delayed healing of atypical fem-
oral fractures with continuation of alendronate [1-3].
There is evidence that bone-forming agents, such as
strontium ranelate or teriparatide, may improve bone
turnover and microarchitecture [4-6]. There have been
reports that indicate bone-forming agents exert a rapid
bone anabolic effect on unhealed atypical fractures asso-
ciated with chronic bisophosphonate use [2,3,7].
Herein, we describe the use of bone-forming agents in
the successful management of atypical femoral fractures
after surgical nailing in patients on long-term alendro-
nate therapy.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The records of patients who sustained subtrochanteric or
diaphyseal femoral fractures and received surgery between
January 2004 and December 2011 at our institution were
reviewed. The definition of an atypical femoral fracture is
based on the ASBMR (American Society for Bone and
Mineral Research) criteria. That is, fractures were located
in subtrochanteric or diaphyseal of femur, typically radio-
graphic features of simple transverse or short oblique con-
figuration without comminution were present, complete
fractures extend through both cortices and may be asso-
ciated with a medial spike, incomplete fractures involved
only the lateral cortex, and with minimal or no trauma
mechanism [8]. The inclusions criteria were that patients
received oral alendronate 70 mg once weekly more than
36 months, and the fractures received surgery on the day of
injury or the next day. Patients with histories of malignancy,
pathologic fractures, metabolic bone diseases, receiving
glucocorticoid or other antiresorptives, were excluded.
Diaphyseal femoral fractures were fixed with antegrade
intramedullary nailing (Howmedica, Rutherford, NJ, U.S.A.)
and subtrochanteric femoral fractures were fixed with
cephalomedullary nailing (PFNA II, Synthes, Oberdorf,
Switzerland). All fractures were fixed with a closed method
on a fracture table.
Follow-up visits and radiographs were performed in
our outpatient clinics at 4, 8, 12, and 16 weeks and vari-
ably thereafter postoperatively. Bony union was defined
as bridging of 3 of the 4 cortices on anteroposterior and
lateral radiographs.
Results
During the 8-year study period, there were 150 subtro-
chanteric and 1104 diaphyseal femoral fractures treated
with surgery at our institution. There were 10 atypicalTable 1 Patient demographics, postoperative treatment, and






1 84 F R Sprain FS
L* Sprain FS
2 88 F R Slipping fall FS
3 80 F R Sprain FS
L* Sprain FS
4 83 F R Slipping fall FS
5 77 F L Sprain FS
R** Sprain FS
6 78 F R Slipping fall FS
7 74 F R Slipping fall ST
ALN, alendronate; BMD, bone mineral density; FS, femoral shaft; ST, subtrochanteric
teriparatide; SR, strontium ranelate.
*Sequential contralateral fractures occurred in the patient continued alendronate af
**Discontinued bone-forming agent after union of the initial fracture, and sequentiafemoral fractures in 7 consecutive osteopenic or osteopor-
otic patients on alendronate therapy for more than
36 months. All patients were female with a mean age of
80.5 years (range, 74–88 years). The mean duration of alen-
dronate therapy was 66.1 months (range, 36–112 months).
All were complete atypical fractures due to an atraumatic
mechanism, such as slipping down or simple sprain injury.
The femoral fracture was subtrochanteric in 1 and diaphy-
seal in 9. Three patients had sequential femoral diaphyseal
fractures (Table 1). The minimum follow-up time was
12 months, and the mean follow-up was 18.9 months
(range, 12–31 months).
In 6 fractures treated earlier in the study period, alendro-
nate was continued after surgery. In 4 fractures treated
later in the study period, alendronate was discontinued and
bone-forming agents were administrated immediately after
surgery. The bone-forming agents were 2 g of strontium
ranelate orally daily or 20 μg of teriparatide subcutane-
ously daily. All fractures achieved union during follow-up.
Mean union time was 23.5 months (range, 18–31 months)
for 6 fractures with continuation of alendronate after sur-
gery, and 4.5 months (range, 4–5 months) for 4 fractures
with discontinuation of alendronate and administration of
bone-forming agents after surgery.
One case (case No. 5) of sequential femoral diaphyseal
fractures revealed an interesting finding. The initial frac-
ture occurred after 63 months of alendronate therapy,
and the union was achieved at 5 months by discontinu-
ation of alendronate and administration of bone-forming
agent after surgery (Figure 1A and 1B). Then bone-
forming agent was stopped after union of fracture. The
patient then received a total knee arthroplasty for right
knee osteoarthritis 11 months later. However, a contra-
lateral atypical femoral fracture was noted 24 months









36 −2.4 IMN ALN 24
62 NA IMN ALN 31
94 −2.8 IMN ALN 20
65 −4.2 IMN ALN 18
112 NA IMN ALN 18
50 −1.0 IMN ALN 30
63 −3.0 IMN TPTD 5
63 NA IMN SR 4
52 −1.8 IMN SR 4
64 −1.7 CMN SR 5
; NA, not available; IMN, intramedullary nail; CMN, cephalomedullary nail; TPTD,
ter surgery.
l contralateral femoral fracture noted 24 months later.
Figure 1 A 77 year-old female suffered from sequential femoral
diaphyseal fractures. (A) The initial femoral fracture happened after
63 months of alendronate therapy. (B) The union was achieved at
5 months by discontinuation of alendronate and administration of
bone-forming agent after surgery. (C) She then received a total knee
arthroplasty for right knee osteoarthritis 11 months later. However,
contralateral femoral fracture was noted 24 months after the initial
fracture. (D) After administration of bone-forming agent, bone was
healed on 4th month post-operatively.
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tration of bone-forming agent, bone was healed on 4th
month post-operatively (Figure 1C and 1D).
Discussion
In the retrospective review of the time to union of atypical
femoral fractures after surgical nailing in patients on alen-
dronate therapy for more than 36 months, we found that
discontinuation of alendronate and administration of
bone-forming agents significantly shortened the time to
union as compared to continuation of alendronate. We
performed surgical nailing in all fractures through a closed
method. Although delayed union was noted in follow-up
of all fractures, we chose observation and waiting rather
than performing revision surgery because 6 fractures withcontinuation of alendronate after surgery showed continu-
ing callus formation as compared with previous radio-
graphs during follow up. In addition, there were neither
postoperative complications nor revision surgeries. How-
ever, Weil et al. described healing of 17 atypical femoral
fractures after intramedullary nailing in only 10 (54%)
patients, with 7 (46%) patients requiring revision surgery.
These secondary procedures included nail dynamization in
4 cases, exchange nailing in 2, and plating in 1. They sup-
posed the higher failure rate seen with bisphosphonate-
related fractures might have been due to an impaired bone
healing process rather than differences in surgical tech-
nique, and qualitative bone defects caused by prolonged
bisphosphonate therapy. The authors suggested more ag-
gressive intraoperative biologic augmentation, such as pri-
mary bone grafting, the use of human recombinant bone
morphogenic protein, or treatment with systemic parathy-
roid hormone analogs due to apparently impaired bone
metabolism associated with bisphosphonate therapy [9].
Atypical femoral fractures are stress fractures asso-
ciated with suppression of bone remodeling induced by
bisphosphonates [10]. Delayed union in such fractures
was reported in previous studies [1-3,8,11]. Some studies
have suggested potential negative effects of bisphospho-
nate on the fracture healing process, leading to the sug-
gestion that treatment should be discontinued during
the healing phase [1,8,12,13]. Some clinical evidence and
a large body of animal data indicate bone-forming agents,
such as strontium ranelate or teriparatide, may accelerate
fracture healing [14-18]. An increase in biomarkers was
also observed in patients with severe osteoporosis who
were undergoing treatment with bone-forming agents,
despite previous treatment with bisphosphonates [19].
Bone-forming agents have been shown to expert a rapid
bone anabolic effect on unhealed atypical fractures asso-
ciated with chronic alendronate use [2,3,7]. In this study,
the time to union of fractures with continuation of alen-
dronate was longer than fractures with discontinuation of
alendronate and administration of bone-forming agents
after surgery. However, our finding is from regular dosage
of bone-forming agents for antiosteoporosis. There is
possibility that increasing the dosage of bone-forming
agents could also reduce the months and increase the
union at a faster space and this provides a platform to
evaluate further.
We have no control group, that is, lack of fracture,
which discontinued alendronate and did not received
bone-forming agents after surgery. Even though previous
studies have reported that bone-forming agents healed
atypical fractures and even with the time course of frac-
ture healing in our patient, we are still not certain that
bone-forming agents played a primary role in the positive
response to therapy or alendronate discontinuation may
have played secondary roles. The bone-forming agent
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for although bone repair requires increased bone forma-
tion, remodeling is also necessary for bone repair. Odvina
et al. reported delayed union with mean time 9.2 months
(range 8 to 12) of 4 atypical femoral fractures despite dis-
continuing alendronate therapy [1]. Visekruna et al. also
reported no fracture healing after 12, 22 and 6 months
after alendronate stopped in 3 atypical femoral fractures.
However, Visekruna speculated that delayed union might
be attributable to the fact that the patients were taking es-
trogen or other medications (glucocorticoids, hormone re-
placement therapy, or raloxifene) that might have resulted
in further suppression of bone turnover [2]. Capeci et al.
treated 7 patients who sustained bilateral simultaneous
or sequential fractures with femoral nailing and discon-
tinuation of alendronate and reported uneventful healing
at an average of 4 months (range, 3 to 5 months) [20].
Alendronate therapy was discontinued at the time of the
second fracture fixation in the patients with sequential
fractures and at the time of injury in the patient with sim-
ultaneous fractures. The 7 patients were not taking gluco-
corticoids, hormone replacement therapy, or raloxifene.
The normal time to fracture union in Capeci’s study is in
contrast to that noted in most reports, which have shown
delayed healing in these patients. However, 4 of these frac-
tures were impending subtrochanteric stress fractures,
which received prophylactic fixation and the usage of
bone-forming agents or not was not documented. The
time to union of fractures which the alendronate has been
discontinued and no bone-forming agents have been ap-
plied seems longer than fractures with discontinuation of
alendronate and administration of bone-forming agents
after surgery.
The sequential femoral diaphyseal fractures revealed
an interesting finding. We believed bone turnover may
remain suppressed several months or years after discon-
tinuation of alendronate. A long skeletal half-life of alen-
dronate which impairs fracture healing has been
described [21], but there was no evidence indicating
what duration of treatment with bone-forming agents
would counteract the effect of alendronate, or that bone-
forming agents could prevent sequential fracture. Fur-
ther study is needed for this issue.
The major limitations of this study are those inherent
within a retrospective case series. This was a small num-
ber of patients with limited data available, and statistical
comparison was therefore not possible. In addition, not
all patients were evaluated for biomarkers as well for
bone pathology.
Conclusions
Discontinuing of alendronate and administration of
bone-forming agents after surgical nailing may promote
union of atypical femoral fractures in patients on long-term alendronate therapy. Further studies are needed to
establish optimal therapeutic guidelines.
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